<DOC>
	<DOCNO>NCT00650871</DOCNO>
	<brief_summary>A study investigate effect GW679769 sleep cognition . Potential subject participate clinical screen visit two-night PSG recording session sleep laboratory . Eligible subject participate three separate two-night PSG session randomize receive placebo one two dos GW679769 60 minute prior bedtime , one treatment session balance order . Each treatment session separate two-week drug-free period occur day week . A safety follow-up visit occur 2 week last treatment session .</brief_summary>
	<brief_title>A Study Evaluate Effects GW679769 Sleep Cognitive Function Subjects With Primary Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Healthy male female subject primary insomnia normal EG may eligible inclusion . clinically significant physical psychiatric illness abnormal sleep pattern .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>GW679769 ,</keyword>
	<keyword>sleep ,</keyword>
	<keyword>cognitive function ,</keyword>
	<keyword>primary insomnia ,</keyword>
	<keyword>polysomnography .</keyword>
</DOC>